34.32
price up icon1.21%   0.41
after-market Dopo l'orario di chiusura: 34.32
loading

Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie

pulisher
Nov 20, 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 12, 2024

LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 EPS Estimate for LENZ Therapeutics Boosted by Analyst - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Has Bullish Outlook for LENZ FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 07, 2024

Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Form 424B3 LENZ Therapeutics, Inc. - StreetInsider.com

Nov 06, 2024
pulisher
Nov 06, 2024

LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer - The Manila Times

Nov 06, 2024
pulisher
Oct 31, 2024

LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag

Oct 31, 2024
pulisher
Oct 30, 2024

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St

Oct 30, 2024
pulisher
Oct 29, 2024

Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter

Oct 29, 2024
pulisher
Oct 28, 2024

LENZ reports positive Chinese study data for far-sightedness drug - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL

Oct 28, 2024
pulisher
Oct 28, 2024

Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World

Oct 28, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 28, 2024

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

Oct 28, 2024
pulisher
Oct 27, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com

Oct 27, 2024
pulisher
Oct 27, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian

Oct 27, 2024
pulisher
Oct 27, 2024

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com

Oct 27, 2024
pulisher
Oct 26, 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat

Oct 26, 2024
pulisher
Oct 22, 2024

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance

Oct 22, 2024
pulisher
Oct 22, 2024

Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail

Oct 22, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com

Oct 21, 2024
pulisher
Oct 21, 2024

Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

One new option listing and ten option delistings on October 21st - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com

Oct 21, 2024
pulisher
Oct 18, 2024

Behind the Bell: LENZ Therapeutics - Nasdaq

Oct 18, 2024
pulisher
Oct 18, 2024

FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, - openPR

Oct 16, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail

Oct 16, 2024
pulisher
Oct 16, 2024

Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 15, 2024

Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

TJX Companies (TJX-N) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 14, 2024

Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World

Oct 14, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Capitalizzazione:     |  Volume (24 ore):